Implementation of precision medicine in (routine) cancer care in Belgium in a fair and equitable way

por Schmitt, T, Delnord, M, Cauët, E, Van Valckenborgh, E, Van Den Bulcke, M
Publicado 2023

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma

por Caers, J, Menu, E, De Raeve, H, Lepage, D, Van Valckenborgh, E, Van Camp, B, Alvarez, E, Vanderkerken, K
Publicado 2008

Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo

por Van Valckenborgh, E, De Raeve, H, Devy, L, Blacher, S, Munaut, C, Noël, A, Van Marck, E, Van Riet, I, Van Camp, B, Vanderkerken, K
Publicado 2002

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment

por Thouvenin, J., Van Marcke, C., Decoster, L., Raicevic, G., Punie, K., Vandenbulcke, M., Salgado, R., Van Valckenborgh, E., Maes, B., Joris, S., Steichel, D. Vander, Vranken, K., Jacobs, S., Dedeurwaerdere, F., Martens, G., Devos, H., Duhoux, F.P., Rasschaert, M., Pauwels, P., Geboes, K., Collignon, J., Tejpar, S., Canon, J.-L., Peeters, M., Rutten, A., Van de Mooter, T., Vermeij, J., Schrijvers, D., Demey, W., Lybaert, W., Van Huysse, J., Mebis, J., Awada, A., Claes, K.B.M., Hebrant, A., Van der Meulen, J., Delafontaine, B., Bempt, I. Vanden, Maetens, J., de Hemptinne, M., Rottey, S., Aftimos, P., De Grève, J.
Publicado 2022